Aum Biosciences to Become a Public Company via Merger with Mountain Crest Acquisition

 

• The transaction reflects a pre-money equity value of $400 million for AUM Biosciences
  

• Transaction is expected to provide $69 million of gross proceeds (assuming no redemptions by Mountain Crest stockholders)

• Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined market opportunity of $10+ billion in metastatic colorectal cancer, and TRK Fusion and mutation cancers

• Mr. Vishal Doshi will continue to lead as the CEO of the publicly traded holding entity; a Mountain Crest representative will join the Board of Directors

• Company to expand US operations and clinical programs

https://finance.yahoo.com/news/aum-biosciences-global-biotechnology-company-090000070.html